Apr 30 2010
Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC") today reported that its innovative asthma drug Laevo-Bambuterol has received approval from China's State Food & Drug Administration's (SFDA) to commence clinical trials (No.2010L01309 and 2010L01399).
R-Bambuterol(R) Hydrochloride Tablets ("Laevo-Bambuterol") is categorized as a Class 1 new drug. Its preclinical studies show that it is more effective and have lower toxicity than Bambuterol, a popular asthma drug currently on the market.
The Company is communicating with experts from the SFDA's Drug Review and Evaluation Center on the designs for clinical trials and expects the new product to launch in 2013-2014.
Source:
Lotus Pharmaceuticals, Inc.
GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes